Retrospective study of thalidomide plus dexamethasone
versus conventional chemotherapy in the relapsed multiple myeloma
patient and the study of melphalan and prednisone versus
melphalan, prednisone, and thalidomide
Mario Boccadoro
Ospedale San Giovanni Battista (Molinette), via Genova 3, 10126
Torino, Italy
Phone: +39.011.6635814
E-mail: mario.boccadoro@unito.it
Thalidomide shows promise in the treatment of multiple myeloma (MM). Questions remain, however, about its efficacy compared with conventional chemo-therapy. [>Read full article in PDF]